Cetera Investment Advisers
ATNM icon

Cetera Investment Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History

Cetera Investment Advisers’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,259
Closed -$20.8K – 4807
2025
Q4 		$20.8K Buy
15,259
+768
+5% +$1.12K ﹤0.01% 4574
2025
Q3 		$23.2K Buy
+14,491
New +$23.6K ﹤0.01% 4482

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Investment Advisers's ATNM Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 15,259 shares — an estimated $20.8K sold.

Cetera Investment Advisers first reported a position in ATNM in Q3 2025 and held it in 2 quarters. The position peaked at $23.2K in Q3 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 15,259 Actinium Pharmaceuticals shares in Q1 2026, an estimated $20.8K.
  • Cetera Investment Advisers first reported a position in Actinium Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Cetera Investment Advisers's Actinium Pharmaceuticals position peaked at $23.2K in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.